MeSH tree: C15.604.515.569.480.150
CAR-T cell therapy is a safe and effective treatment for diffuse large B-cell lymphoma (DLBCL), even for patients regarded as high risk due to comorbidities.
Dec 11, 2023
0
43
Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine say a new combination of antibody therapies produced a "surprisingly high" response ...
Dec 11, 2023
0
43
The Malaghan Institute of Medical Research, in collaboration with Wellington Zhaotai Therapies Limited, today announced results of its phase 1 dose escalation trial of a new third generation anti-CD19 chimeric antigen receptor ...
Dec 11, 2023
0
51
Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100% complete response (CR) rate at the higher dose levels studied in the trial, ...
Dec 11, 2023
0
40
For patients with diffuse large B-cell lymphoma (DLBCL), the chimeric antigen receptor T-cell therapies (CAR-T) axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are not cost-effective, according to ...
Dec 5, 2023
0
30
A surprising mechanism that makes some cancers treatment-resistant has been discovered by Weill Cornell Medicine and NewYork-Presbyterian investigators. The mechanism, which involves the shuttling of messenger RNAs (mRNAs) ...
Nov 2, 2023
0
47
Some patients with aggressive lymphomas face a rare but clinically challenging prognosis when their cancer spreads to the central nervous system (CNS) or relapses there.
Sep 14, 2023
0
36
Preliminary results of a first-in-human study show manageable toxicity and preliminary antitumor activity of a potential second generation epigenetic therapy for advanced solid tumors
Jul 26, 2023
0
32
A team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS), led by Assistant Professor Anand Jeyasekharan, has discovered a unique combination of oncogenes ...
Jul 19, 2023
0
47
In a multi-center phase 1 and 2 trial (BRUIN, NCT03740529), researchers from leading cancer centers across the globe, including the Medical College of Wisconsin (MCW) in Milwaukee, tested Bruton tyrosine kinase inhibitor ...
Jun 2, 2023
0
51
